Investigation of Doxorubicin Efficiency in Some Hematological Parameters in Women with Breast Cancer in Iraq
DOI:
https://doi.org/10.32792/utq/utjsci/v11i2.1304Keywords:
Doxorubicin, Breast cancer, , Hematological parameters, ChemotherapyAbstract
Breast cancer is a prevalent disease among females worldwide. Low levels of doxorubicin are used as a standard treatment, predicting severity, mortality, and treatment compliance. This study aims to explore differences in hematological profiles and effects of doxorubicin in breast cancer patients. A descriptive cross-sectional study in Thi-Qar province compared the hematological parameter of the forty Female Breast Cancer patients. Patients’ data were then grouped according to four categories: chemotherapy sessions. It will take 8 months of chemotherapy and will involve one session every 21 days. The results showed that the patients had an average white blood cell count of 5.85, lower than the control group's 8.8, and a mean hemoglobin of 10.99. The patient group had a mean platelet count of 321.7, higher than the control group's 251.4, indicating a statistically significant difference at a significance level of α ≤ 0.05. Doxorubicincontinues to be used in the management of breast cancer; nonetheless, its utilization is limited because of toxicity, including cardiotoxicity and myelosuppression. As it is with tradition in advanced breast cancer, the vast majority of the submitted patients experienced some form of hematological alteration, which includes anemia, leucopenia, and thrombocytosis. Hematologic studies are thus very relevant in breast cancer management, its progression, and also in detection of some sequential malignancies related to breast cancer.
Received: 2024-09-20
Revised:2024-10-12
Accepted: 2024-11-04
References
[1] A. J. Hadi, S. J. Mohammed, and M. A. Dabbi, "Physiological study of liver and kidney of female patient with breast cancer which treated with different doses of Chemotherapy," Current Clinical and Medical Education, vol. 2, pp. 17-24, 2024.
[2] A. Dias-Carvalho, M. Ferreira, A. Reis-Mendes, R. Ferreira, M. de Lourdes Bastos, E. Fernandes, et al., "Doxorubicin-induced neurotoxicity differently affects the hippocampal formation subregions in adult mice," Heliyon, 2024.
[3] L. Koochakzadeh, M. Mahbod, R. Pakzad, D. Jafari, F. Khoshhal, A. Yekta, et al., "Establishing normal ranges of hematological parameters from an Iranian healthy population: A population-based cross-sectional study of hospital data," Acta Medica Iranica, pp. 571-576, 2018.
[4] L. Chen, X. Kong, C. Yan, Y. Fang, and J. Wang, "The research progress on the prognostic value of the common hematological parameters in peripheral venous blood in breast cancer," OncoTargets and therapy, pp. 1397-1412, 2020.
[5]U. Mahlknecht and S. Kaiser, "Age-related changes in peripheral blood counts in humans," ExpErimEntal and thErapEutic mEdicinE, vol. 1, pp. 1019-1025, 2010.
[6]S. Khan, S. Khoso, S. Memon, A. Adeel, and G. Nabi, "Study of some Hematological parameters as Biomarker for breast Cancer population of Sindh," Sindh University Research Journal-SURJ (Science Series), vol. 49, 2017.
[7]L. O. Ali, "Study effect of breast cancer on some hematological and biochemical parameters in Babylon Province, Iraq," Journal of Pharmacy and Biological Sciences, vol. 9, pp. 20-24, 2014.
[8]B. Divsalar, P. Heydari, G. Habibollah, and G. Tamaddon, "Hematological Parameters Changes in Patients with Breast Cancer," Clinical laboratory, 2021.
[9]E. Etim, M. Emokpae, A. Ohwonigho, and A. Yusuf, "Association of platelet count and platelet indices with stages of women breast cancer in Yola, Nigeria," Hematol Transfus Int J, vol. 6, p. 00145, 2018.
[10]A. Kaser, G. Brandacher, W. Steurer, S. Kaser, F. A. Offner, H. Zoller, et al., "Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis," Blood, The Journal of the American Society of Hematology, vol. 98, pp. 2720-2725, 2001.
[11]S. Shrivastava, N. Singh, A. K. Nigam, S. S. Chandel, R. Shrivastava, and S. Kumar, "Comparative study of hematological parameters along with effect of chemotherapy and radiotherapy in different stages of breast cancer," International Journal of Research in Medical Sciences, vol. 5, pp. 311-315, 2016.
[12]P. Chauhan, R. Yadav, V. Kaushal, and P. Beniwal, "Evaluation of serum biochemical profile of breast cancer patients," Int J Med Res Health Sci, vol. 5, p. 1, 2016.
[13]S. Croci, G. Pedrazzi, G. Passeri, R. Delsignore, and I. Ortalli, "Red cell Hb oxidation of healthy subjects compared to breast cancer patients," Anticancer research, vol. 22, pp. 2903-2906, 2002.
[14] E. Akanni, A. Oguntola, M. Adeoti, and S. Agodirin, "Haematological Parameters in Female patents in South Western Nigeria," Int J Med Health Sci, vol. 2, pp. 398-401, 2013.
[15]R. Hussein, S. Sultan, and M. Shabil, "Effect of doxorubicin and cyclophosphamide on some hematological parameters in women with breast cancer in iraq," Plant Archives, vol. 20, pp. 503-5608, 2020.
[16]B. Melichar, D. Solichova, K. Melicharova, H. Urminska, A. Ryska, and M. Cermanova, "Systemic immune activation, anemia and thrombocytosis in breast cancer patients treated by doxorubicin and paclitaxel," Pteridines, vol. 17, pp. 107-114, 2006.
Downloads
Published
Issue
Section
Categories
License
Copyright (c) 2024 University of Thi-Qar Journal of Science
This work is licensed under a Creative Commons Attribution 4.0 International License.
